Yan-Hua Zheng (Yanhua Zheng)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Topics

Prognostic Factors

Hodgkin Lymphoma

Multiple Myeloma

Top Venues

Journal of oncology

Clinical and experimental medicine

Therapeutic advances in hematology

Journal of immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Yan-Hua Zheng, Biao Tian, Wei-Wei Qin, Qing-Wen Zhu, Juan Feng, Wu-Yue Hu, Ren-An Chen, Li Liu
Distribution and survival outcomes of primary head and neck hematolymphoid neoplasms in older people: a population-based study. Clinical and experimental medicine (2023)
Yan-Hua Zheng, Biao Tian, Wei-Wei Qin, Qing-Wen Zhu, Juan Feng, Wu-Yue Hu, Ren-An Chen, Li Liu
Distribution and survival outcomes of primary head and neck hematolymphoid neoplasms in older people: a population-based study. Clinical and experimental medicine (2023)
Yan-Hua Zheng, Biao Tian, Wei-Wei Qin, Qing-Wen Zhu, Juan Feng, Wu-Yue Hu, Ren-An Chen, Li Liu
Distribution and survival outcomes of primary head and neck hematolymphoid neoplasms in older people: a population-based study. Clinical and experimental medicine (2023)
Hong-Yuan Shen, Hai-Long Tang, Yan-Hua Zheng, Juan Feng, Bao-Xia Dong, Xie-Qun Chen
The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects. Journal of oncology 2022 (2022)
Yang-Jia Cao, Yan-Hua Zheng, Qing Li, Jin Zheng, Li-Tian Ma, Can-Jun Zhao, Tian Li
MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors. Journal of oncology 2022 (2022)
Guang Li, Yan-Ping Song, Yao Lv, Zhen-Zhen Li, Yan-Hua Zheng
Clinical Characteristics and Prognostic Analysis of Multiple Myeloma with Extramedullary Disease: A SEER-Based Study. Journal of oncology 2021 (2021)
Chen-Xin Liu, Tian-Qi Xu, Li Xu, Pan-Pan Wang, Chun Cao, Guang-Xun Gao, Yan-Hua Zheng
Primary lymphoma of bone: a population-based study of 2558 patients. Therapeutic advances in hematology 11 (2020)
Guang Li, Yan-Hua Zheng, Li Xu, Juan Feng, Hai-Long Tang, Cheng Luo, Yan-Ping Song, Xie-Qun Chen
BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis. Therapeutic advances in hematology 11 (2020)
Yan-Hua Zheng, Hongyuan Shen, Li Xu, Juan Feng, Hailong Tang, Na Zhang, Xie-Qun Chen, Guang-Xun Gao
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials. Journal of immunology research 2018 (2018)